Pharmacists in Sleepy Eye, MN Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Kevin Currans, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 121 1st Ave S, Sleepy Eye, MN 56085 Phone: 507-794-3631 |
Randall Armbruster Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 121 1st Ave S, Sleepy Eye, MN 56085 Phone: 507-794-3631 Fax: 507-794-7818 |
 Samantha Armbruster, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 121 1st Ave S, Sleepy Eye, MN 56085 Phone: 507-794-3631 |
Nikki Heiderscheidt Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 121 1st Ave S, Sleepy Eye, MN 56085 Phone: 507-794-3631 |
News Archive
Pancreatic cancer patients with BRCA1 or BRCA2 mutations fare better on platinum-based chemotherapy
A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations.
Eating disorders increase risk of premature birth
Pregnant women with eating disorders should undergo extended pregnancy screenings considering their increased risk of complications. That is the conclusion from a study by researchers at Karolinska Institutet in Sweden published in the journal JAMA Psychiatry.
New therapeutic ultrasound approach could lead to an invisible knife for noninvasive surgery
A carbon-nanotube-coated lens that converts light to sound can focus high-pressure sound waves to finer points than ever before. The University of Michigan engineering researchers who developed the new therapeutic ultrasound approach say it could lead to an invisible knife for noninvasive surgery.
Bionovo initiates Menerba Phase 3 trial in menopausal hot flashes
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.
New target for Hodgkin lymphoma
Dana-Farber Cancer Institute scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells.
› Verified 4 days ago